Synairgen plc (LON:SNG – Get Rating) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 19.75 ($0.24) and traded as low as GBX 12.50 ($0.15). Synairgen shares last traded at GBX 13.85 ($0.17), with a volume of 1,251,966 shares traded.
Synairgen Stock Performance
The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.35. The stock has a market cap of £27.89 million and a PE ratio of -0.57. The company's 50 day simple moving average is GBX 15.51 and its 200 day simple moving average is GBX 19.75.
Synairgen Company Profile
(Get Rating)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Read More
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
在週五的交易中,Synairgen plc(倫敦股票代碼:SNG-GET Rating)的股價跌破了200日移動均線。該股的200日移動均線為19.75英鎊(合0.24美元),交易價格低至12.50英鎊(合0.15美元)。Synairgen的股票最後交易價格為13.85英鎊(0.17美元),總成交量為1,251,966股。
Synairgen股票表現
該公司的負債權益比率為0.09,速動比率為6.35,流動比率為6.35。該股市值2789萬GB,本益比為-0.57。該公司的50日簡單移動均線切入位在15.51,200日簡單移動均線切入位在19.75.
Synairgen公司簡介
(獲取評級)
Synairgen plc發現和開發治療呼吸系統疾病的藥物。該公司開發的產品有:治療新冠肺炎的乙型吸入型幹擾素SG001;治療感冒和流感引起的哮喘的乙型幹擾素吸入劑;治療或預防慢性阻塞性肺病的乙型幹擾素第二階段臨床試驗;以及治療特發性肺纖維化的LXL2抑制劑。
閱讀更多內容
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年晶片需求回升,提振銷售觀點
- KLA公司:在動盪不安的半市場中站穩腳跟
接受Synairgen Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Synairgen和相關公司的最新新聞和分析師評級的每日簡明摘要。